ALL expression, in children with B-cell precursor CRLF2 deletion, but not high IKZF1 signature and BCR-ABL1-like Independent prognostic value of

[1]  M. Loh,et al.  Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. , 2013, Blood.

[2]  B. Meissner,et al.  IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol , 2010, Haematologica.

[3]  M. Loh,et al.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.

[4]  J. Meijerink,et al.  Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations , 2012, Leukemia.

[5]  O. Haas,et al.  Treatment outcome of CRLF2 ‐rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP‐BFM and UK NCRI‐CCLG study groups , 2012, British journal of haematology.

[6]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[7]  R. Foà,et al.  IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia , 2012, PloS one.

[8]  M. Loh,et al.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. , 2012, Blood.

[9]  Markus Werner,et al.  FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination , 2012, The Journal of experimental medicine.

[10]  B. Calabretta,et al.  c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells , 2011, Leukemia.

[11]  Michael N. Edmonson,et al.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[12]  A. Gavrilov,et al.  Identification of c-Myb Target Genes in K562 Cells Reveals a Role for c-Myb as a Master Regulator. , 2011, Genes & cancer.

[13]  Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias , 2011, The Journal of experimental medicine.

[14]  S. Richards,et al.  Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. , 2011, Blood.

[15]  C. V. D. Schoot,et al.  Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia , 2011, Leukemia.

[16]  M. Merkenschlager.  Ikaros in immune receptor signaling, lymphocyte differentiation, and function , 2010, FEBS letters.

[17]  Kevin K Dobbin,et al.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.

[18]  Takashi Akasaka,et al.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.

[19]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[20]  A. Veerman,et al.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL , 2010, Leukemia.

[21]  F. Sigaux,et al.  Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia , 2010, Leukemia.

[22]  H. Cavé,et al.  Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia , 2010, Leukemia.

[23]  W. Kamps,et al.  Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004 , 2010, Leukemia.

[24]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[25]  G. Escherich,et al.  Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97 , 2010, Leukemia.

[26]  P. D. Dal Cin,et al.  Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[27]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[28]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[29]  N. Heisterkamp,et al.  Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS function , 2009, The Journal of experimental medicine.

[30]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[31]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[32]  J. Dongen,et al.  MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009 .

[33]  Inge Jonassen,et al.  Characterization of Early Stages of Human B Cell Development by Gene Expression Profiling1 , 2007, The Journal of Immunology.

[34]  W. Lee,et al.  Stage-Specific Expression of Two Neighboring Crlz1 and IgJ Genes during B Cell Development Is Regulated by Their Chromatin Accessibility and Histone Acetylation1 , 2006, The Journal of Immunology.

[35]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .